Cargando…

Prostate cancer screening—when to start and how to screen?

Prostate-specific antigen (PSA) screening reduces prostate cancer (PCa) mortality; however such screening may lead to harm in terms of overdiagnosis and overtreatment. Therefore, upfront shared decision making involving a discussion about pros and cons between a physician and a patient is crucial. T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kohestani, Kimia, Chilov, Marina, Carlsson, Sigrid V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2018
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5861291/ https://www.ncbi.nlm.nih.gov/pubmed/29594018 http://dx.doi.org/10.21037/tau.2017.12.25

Ejemplares similares

The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate
por: Kohestani, Kimia, et al.
Publicado: (2021)

Bi- or multiparametric MRI in a sequential screening program for prostate cancer with PSA followed by MRI? Results from the Göteborg prostate cancer screening 2 trial
por: Wallström, Jonas, et al.
Publicado: (2021)

Who and when should we screen for prostate cancer? Interviews with key opinion leaders
por: Carlsson, Sigrid, et al.
Publicado: (2015)

Colorectal Cancer Screening—Who, How, and When?
por: Bevan, Roisin, et al.
Publicado: (2018)

Stopping screening, when and how?
por: Hugosson, Jonas
Publicado: (2018)

When and how to Screen!
por: Ekbom, A.
Publicado: (2020)

Endocrine treatment in advanced prostate cancer: When to start?
por: Choudhrie, A. V., et al.
Publicado: (2009)

Citrate: How to Get Started and What, When, and How to Monitor?
por: Honore, Patrick M., et al.
Publicado: (2018)

Lifetime Benefits and Harms of Prostate-Specific Antigen–Based Risk-Stratified Screening for Prostate Cancer
por: Heijnsdijk, Eveline A M, et al.
Publicado: (2020)

Extracorporeal gas exchange: when to start and how to end?
por: Gattinoni, L., et al.
Publicado: (2019)

When should screening of pediatric trauma patients for adult behaviors start?
por: Maung, Adrian A, et al.
Publicado: (2018)

Screening for MAFLD: who, when and how?
por: Pal, Shreya C., et al.
Publicado: (2023)

Screening for nonalcoholic fatty liver disease-when, who and how?
por: Dietrich, Christoph G, et al.
Publicado: (2021)

Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study
por: Carlsson, Sigrid, et al.
Publicado: (2014)

Pediatric eye screening – Why, when, and how
por: Honavar, Santosh G
Publicado: (2018)

When to screen and not to screen
por: Cruickshanks, Nichola
Publicado: (2014)

When to start and when to stop antifibrotic therapies
por: Torrisi, Sebastiano Emanuele, et al.
Publicado: (2017)

The countdown to type 1 diabetes: when, how and why does the clock start?
por: Ziegler, Anette-Gabriele
Publicado: (2023)

The science of rapid start—From the when to the how of antiretroviral initiation
por: Geng, Elvin H., et al.
Publicado: (2017)

Impact of cause of death adjudication on the results of the European prostate cancer screening trial
por: Walter, Stephen D, et al.
Publicado: (2017)

Prostate cancer screening in Europe and Asia
por: Zhang, Kai, et al.
Publicado: (2017)

Towards personalized prostate cancer screening
por: Filella, Xavier
Publicado: (2020)

Role of mpMRI of the prostate in screening for prostate cancer
por: Wallis, Christopher J. D., et al.
Publicado: (2017)

Screening for Prostate Cancer: The Debate Continues
por: Matrana, Marc R., et al.
Publicado: (2013)

Prostate Cancer – To screen, or not to screen, is that the question?
por: Rosser, Charles J
Publicado: (2008)

To screen or not to screen: the prostate cancer dilemma
por: Stone, Nelson N, et al.
Publicado: (2015)

Randomised prostate cancer screening trial: 20 year follow-up
por: Sandblom, Gabriel, et al.
Publicado: (2011)

Association of Baseline Prostate-Specific Antigen Level With Long-term Diagnosis of Clinically Significant Prostate Cancer Among Patients Aged 55 to 60 Years: A Secondary Analysis of a Cohort in the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
por: Kovac, Evan, et al.
Publicado: (2020)

With increasing trends of prostate cancer in the Saudi Arabia and Arab World: Should we start screening programs?
por: Arafa, Mostafa A, et al.
Publicado: (2017)

Locoregional therapy in hepatocellular carcinoma: when to start and when to stop and when to revisit
por: Lee, J.J.X., et al.
Publicado: (2021)

Start-Up of the Colorectal Cancer Screening Demonstration Program
por: DeGroff, Amy, et al.
Publicado: (2008)

Post-Traumatic Hypopituitarism—Who Should Be Screened, When, and How?
por: Quinn, Mark, et al.
Publicado: (2018)

Tailored therapeutic decision of rheumatoid arthritis using proteomic strategies: how to start and when to stop?
por: Chen, Shuo-Fu, et al.
Publicado: (2023)

Get momentum: how to start when you're stuck
por: Womack, Jason W, et al.
Publicado: (2016)

Ready to screen? Start with the goal in mind
por: Gilbert, Clare
Publicado: (2017)

How Microbiology started
por: Collins, Peter
Publicado: (2022)

Need for and relevance of prostate cancer screening in Nigeria
por: Akinremi, TO, et al.
Publicado: (2014)

Advice About Screening for Prostate Cancer With Prostate-Specific Antigen
por: Jean-Pierre, Gannel
Publicado: (2017)

Genetic screening for multiple endocrine neoplasia syndrome type 1 (MEN-1): when and how
por: Falchetti, Alberto
Publicado: (2010)

Prostate cancer screening
por: Eastham, James
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_4cre2mkr6h8mm53mqkopm0trqc